Sun Pharma Advanced Research Company receives Rs 149.99 crore for warrant allotment

Yash Agarwal — Mon, 25 May 2026 15:09:21 +0000

Sun Pharma Advanced Research Company (SPARC) has received a substantial sum of ₹149,99,64,500 from Shanghvi Finance Private Limited towards the preferential allotment of warrants. This financial transaction is part of SPARC’s compliance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The allotment involves 3,85,10,000 warrants, and the funds were received on 19 May 2026. The transaction was processed through ICICI Bank‘s Mumbai-Nariman Point branch, with multiple UTR numbers confirming the receipt.

This financial move aligns with SPARC’s strategic objectives to bolster its capital structure and maintain regulatory compliance. The receipt of funds from Shanghvi Finance Private Limited, a significant stakeholder, underscores the continued confidence in SPARC’s growth trajectory and financial health.

The statutory auditor, S R B C & Co LLP, has issued a certificate confirming SPARC’s compliance with the relevant regulatory requirements, ensuring that all necessary documentation is maintained as per the ICDR Regulations.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Shanghvi Finance | Business Upturn

Sun Pharma Advanced Research Company receives Rs 149.99 crore for warrant allotment